Trial Profile
Influence of mucosal immunity and viral persistence on CD4/CD8 ratio following initiation of antiretroviral therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 May 2015
Price :
$35
*
At a glance
- Drugs Efavirenz (Primary) ; Maraviroc (Primary) ; Raltegravir (Primary) ; Emtricitabine/tenofovir
- Indications HIV infections
- Focus Pharmacodynamics
- 18 May 2015 New trial record